No Data
Tianjin Chase Sun Pharmaceutical (300026.SZ): No CRO or CXO Business at the moment.
On December 12, at the investor interaction platform, Tianjin Chase Sun Pharmaceutical (300026.SZ) stated that the main Business it engages in can be roughly divided into Traditional Chinese Medicine granules, finished drugs, medical instruments, raw and auxiliary materials, healthcare services, and intelligent supply chain for drugs and medical devices, with no CRO or CXO Business at present.
Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Tianjin Chase Sun Pharmaceutical (300026.SZ): There is currently no layout for the traditional chinese medicine industry chain and traditional chinese medicine diagnosis and treatment services in xiong'an.
Gelonghui, November 28丨tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that there is currently no layout for the traditional chinese medicine industry chain and traditional chinese medicine diagnosis and treatment service business in xiong'an.
Tianjin Chase Sun Pharmaceutical (300026.SZ): Ketorolac Tromethamine Injection has passed the consistency evaluation for generic drugs.
On November 27th, Gelonghui reported that tianjin chase sun pharmaceutical (300026.SZ) announced that recently, tianjin chase sun pharmaceutical Co., Ltd. received the "Notice of Approval for Supplementary Application of Pharmaceuticals" issued by the National Medical Products Administration (Notice No.: 2024B05486). Upon review, the product passed the consistency evaluation for the quality and efficacy of generic drugs. Ketorolac tromethamine injection is an analgesic medication. It can be administered intravenously or intramuscularly. It is typically used for short-term postoperative analgesia, with a strong analgesic effect, achieving short-term pain relief comparable to that of opioid analgesics (such as morphine).
tianjin chase sun pharmaceutical (300026.SZ): The company's Class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.
Gelonghui November 6th | tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that the company's Class I innovative lung cancer drug PTS does not involve genetic testing before clinical application.
tianjin chase sun pharmaceutical (300026.SZ): No products are involved in this year's medical insurance negotiations.
Gelonghui November 1st, tianjin chase sun pharmaceutical (300026.SZ) stated on the investor interaction platform that the company currently has no products involved in this year's medical insurance negotiations.
The One-year Shareholder Returns and Company Earnings Persist Lower as Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Stock Falls a Further 6.1% in Past Week
No Data
